NCT03208933View on ClinicalTrials.gov

Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

November 13, 2019

Study Completion Date

November 13, 2019

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Pirfenidone

Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.

Trial Locations (11)

119992

I.M. Sechenov First Moscow State Medical University: The E.M. Tareyev Clinic, Moscow

129110

Vladimirskiy Regional Scientific Research Inst., Moscow

197022

"SBEI HPE The First St.Petersburg State Medical University n.a. acad. I.P.Pavlovaof MoH of RF", Saint Petersburg

394066

"Budget Institution of Healthcare of Voronezh Region Voronezh Regional Clinical Hospital #1", Voronezh

450005

Republican clinical hospital named after G.G. Kuvatov, Ufa

630087

State Novosibirsk Regional Clinical Hospital, Novosibirsk

656024

"Regional State Budgetary Institution of Healthcare Regional Cinilcal Hospital; Pulmonology", Barnaul

Unknown

GBUZ Regional clinical hospital #4, Chelyabinsk

Central NII tuberkuleza RAMN, Moscow

Pulmonologii NII FMBA of Russia, Moscow

New Hospital, Yekaterinburg

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03208933 - Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). | Biotech Hunter | Biotech Hunter